Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

The Danish pharmaceutical developer updated its 2023 guidance. It raised its projected growth rates for both sales and operating profit.

Why Novo Nordisk Stock Raced Higher Today

Novo Nordisk now expects 2023 sales growth of between 32% and 38%.

Novo Nordisk Raises Sales Outlook on Soaring Demand for Ozempic and Wegovy

Campbell Soup

General Mills

Hershey

Kellogg

Kraft Heinz

Eli Lilly

Mondelez

McCormick

Invesco Dynamic Food & Beverage ETF

J. M. Smucker

Simply Good Foods

Tyson Foods

Hostess Brands

Consumer Staples Select Sector SPDR Fund

Bernstein analysts set out to determine that, analyzing online data to better understand changes in eating habits — and to evaluate which food companies may be most affected. They published the results in a report Friday.

What exactly are patients taking new weight-loss drugs eating and what are they avoiding? Bernstein asked them.

Novo Nordisk's forecast only confirms the frenzy for Wegovy and Ozempic, which patients seek for their ability to help them lose significant weight over time.

Novo Nordisk hikes outlook on soaring demand for Wegovy, Ozempic

Novo Nordisk (NYSE:NVO)'s shares have jumped after it lifted annual guidance, predicting a boost from higher sales of its diabetes drug Ozempic in the US. Europe's most valuable company, after recently dethroning LVMH, said that for the third-quarter its sales jumped 38% year-on-year at constant currency, while Ebit rose 47%.

Novo Nordisk ups guidance, sees higher sales of Ozempic

Novo Nordisk NVO, +1.36% on Friday boosted its full-year 2023 profit and sales outlook, reflecting heightened expectations for Ozempic and Wegovy sales. The company now projects full-year sales growth of 32% to 38%, up from 27% to 33% previously, and operating profit growth of 40% to 46%, up from 31% to 37% previously.

Novo Nordisk boosts sales and profit outlook, buoyed by Ozempic and Wegovy

Novo Nordisk has raised the outlook for its full-year sales and operating profit, the Danish drugmaker said in a statement on Friday.

Novo Nordisk raises outlook for full-year sales, operating profit

Bagsværd, Denmark, 13 October 2023 – Novo Nordisk today announced that the sales and operating profit growth at constant exchange rates (CER) for the first nine months of 2023 and that the full-year sales and operating profit outlook at CER have been raised.

Novo Nordisk raises sales and operating profit outlook for 2023

Hormel Foods

Coca-Cola

PepsiCo

1 Dividend Legend Potentially Set To Soar And 2 To Ignore

Conagra Brands

Walmart

But does Novo Nordisk's good fortune translate to lower sales for companies like Walmart Inc. NYSE: WMT, Coca-Cola Co. NYSE: KO and PepsiCo Inc. NASDAQ: PEP?

Will Higher Ozempic Use Mean Slimmed-Down Food Sales?

Novo Nordisk on Thursday warned of a surge in counterfeit versions of its weight-loss drug Wegovy and diabetes drug Ozempic offered online as illegal traders seek to take advantage of their huge popularity, putting users' health at risk.

Novo Nordisk warns online offers of fake Ozempic, Wegovy are on the rise

Boston Scientific

CareTrust REIT

Exact Sciences

Life Time Group Holdings

Topgolf Callaway Brands Corp

Royal Caribbean Cruises

There's no doubt that America is aging. The numbers do not lie.

7 Affordable Stocks to Invest in as America's Population Ages

Shares of biotechnology firm CSL fell to a four-year low on Thursday, after rival Novo Nordisk's Ozempic drug showed early signs of success in delaying the progression of kidney disease in diabetes patients.

Australia's CSL tanks as Novo Nordisk's kidney trial success stokes competition concerns

NVIDIA

Tesla

Competitive moats symbolize a company's sustainable advantage, protecting it from competitors and external threats. Three standout examples illustrate this principle vividly.

The 3 Widest Competitive Moats on Wall Street

American depositary receipts (ADRs) of Novo Nordisk (NOVO) jumped over 6% in early trading on Wednesday, while shares of kidney dialysis machine and insulin pump makers tumbled, after the drug maker halted a test of its Ozempic diabetes medicine because of its early success in treating kidney problems.

Ozempic Study Shakes Up Market for Kidney and Insulin Treatments

Novo Nordisk (NVO) is set to stop its kidney outcomes study on Ozempic based on interim analysis results that met certain pre-specified efficacy criteria for early closure. The stock rises 5.2%.

Novo Nordisk (NVO) Up on Positive Kidney Outcomes Study Update

Baxter

Fresenius Medical Care

Over $5bn in value was wiped from the three main operators in the dialysis market after a clinical trial update that offers hope for thousands of diabetes sufferers with kidney disease. Earlier, Novo Nordisk (NYSE:NVO) revealed that its Ozempic – a weekly jab which also doubles as a weight-loss aid – had proven successful in treating the new patient group mentioned above.

Novo Nordisk data knocks $5bn from the value of three leading dialysis companies

Novo Nordisk stock popped Wednesday after the company hinted its weight-loss drug showed early promise in kidney disease treatment.

Novo Nordisk Pops After Hinting Weight-Loss Drug Also Treats Kidney Disease

DaVita

Markets were poised to move higher again on Wednesday morning. Shares of Novo Nordisk climbed on good news from a study of its drug Ozempic on kidney patients.

Ozempic Is Moving a Bunch of Stocks Wednesday Morning

Novo Nordisk's Ozempic already is poised to disrupt a range of industries via its weight-loss benefits. Now it threatens companies which treat kidney failure.

Novo Nordisk Halts Ozempic Kidney Trial. Why It's Bad for DaVita.

Silk Road Medical Inc

Shares of Thor Industries Inc. THO rose 2% after the RV maker said its board authorized a 7% dividend increase to 48 cents a share.

Novo Nordisk shares rise, Silk Road Medical stock slumps and other movers

Denmark-based drugmaker Novo Nordisk said on Tuesday it will stop a trial studying Ozempic, its popular diabetes and weight-loss drug, to treat renal impairment in diabetes patients, as its independent data monitoring board concluded the drug had met efficacy criteria in an interim analysis.

Novo Nordisk to stop Ozempic trial to treat renal impairment early

Novo Nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, FLOW, based on interim analysis Bagsværd, Denmark, 10 October 2023 – Novo Nordisk today announced the decision to stop the kidney outcomes trial FLOW (Effect of semaglutide versus placebo on the progression of renal impairment in people with type 2 diabetes and chronic kidney disease). The decision to stop the trial is based on a recommendation from the independent Data Monitoring Committee (DMC) concluding that the results from an interim analysis met certain pre-specified criteria for stopping the trial early for efficacy.

Novo Nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, FLOW, based on interim analysis

How Ozempic and Wegovy turned Novo Nordisk into a $400 billion company

The number of U.S. employers who cover obesity medications, including Wegovy from Novo Nordisk that belongs to a class of GLP-1 drugs, could nearly double next year, according to a survey. The survey of 502 employers by Accolade , a company that provides healthcare programs for employers, and research firm Savanta said 43% of the employers it polled could cover GLP-1 drugs in 2024 compared to 25% that cover them now.

U.S. employers covering weight-loss drugs could nearly double in 2024 - survey

News for Novo Nordisk Stock (NVO)